SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from...
Apotex Generic Pomalidomide Receives Approval in US
Pomavid®; Our dedication to shaping hope
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
Teva Pharm Generic Pomalidomide Receives Approval in the U.S.
Mylan's Generic Pomalidomide Receives Approval in the U.S.
STOCKHOLM, Jan. 13, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the data from the randomized head-to-head phase 3 OCEAN study, evaluating the efficacy and safety of melflufen (INN melphalan flufenamide) plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma (RRMM) that have received 2-4 prior lines of therapy, have been published in the Lancet Hematology. The OCEAN study was initiated in 2017 and includes 495 patients from 108 hospitals in 21 countries across Europe, North America, and Asia.
Pharmascience's Generic Bortezomib Receives Approval in the U.S.
Dr. Reddy's Generic Pomalidomide Receives Approval in the U.S.
Dr. Reddy`s Laboratories`s Generic Pomalidomide Receives Tentative Approval In US